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Abstract
The aim of the present study was to evaluate the activity and tolerability of low-dose oral ethinylestradiol and
luteinizing hormone-releasing hormone analogue with concomitant low-dose acetylsalicylic acid for advanced
castrate-resistant prostate cancer. Of the 32 enrolled patients, a prostate-speciﬁc antigen response was
observed in 19 (59.3%). The median progression-free survival was 9.4 months. Treatment was generally well
tolerated, and no grade 3/4 toxicity was observed.
Background: The aim of the present study was to evaluate the activity and tolerability of low-dose oral ethinylestradiol
(EE) and luteinizing hormone-releasing hormone analogue with concomitant low-dose acetylsalicylic acid (ASA) as a
thromboprophylactic agent for advanced castrate-resistant prostate cancer (CRPC). Patients and Methods: The
patients received an EE dose of 150 mg daily (50 mg 3 times daily) and an ASA dose of 100 mg once daily. The primary
endpoint was the prostate-speciﬁc antigen response. Results: A total of 32 patients were enrolled. A PSA response
was observed in 19 patients (59.3%; 95% conﬁdence interval [CI], 41%-76%). The median progression-free survival
was 9.4 months (95% CI, 6.5-14.1 months). The treatment was generally well tolerated and no grade 3-4 toxicity was
observed. Only 1 patient interrupted EE because of a cardiac event and 1 patient experienced grade 2 nausea and
vomiting. No major bleeding occurred. Conclusion: Low-dose EE with concomitant low-dose ASA is safe, showing
potential activity in patients with advanced CRPC, and should be investigated further.
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Introduction
Prostate cancer is the second leading cause of cancer-related death
in men in western countries. Androgen-deprivation, either from
surgery (bilateral orchiectomy) or administration of gonadotropin-
releasing hormone agonists or antagonists therapy, is considered
the ﬁrst approach for advanced and metastatic disease.1 However,
most of the patients develop progression toward castration-resistant
prostate cancer (CRPC). In this setting, docetaxel plus prednisone
was the ﬁrst therapeutic approach able to improve survival
compared with older regimens.2,3 Recently, new hormonal agents
have been added to the standard chemotherapy agents, including
abiraterone acetate, an irreversible P450c17 (CYP17) inhibitor that
blocks androgen biosynthesis, and enzalutamide, a second-
generation androgen receptor antagonist.4 The beneﬁt of these
drugs in the CRPC setting has been widely demonstrated.4
Oral ethinylestradiol (EE) previously demonstrated preclinical
and clinical activity in prostate cancer. Several studies have reported
that estrogens have a direct toxic effect on prostate cancer cells by
induction of apoptosis, in addition to indirect antitumor activity
related to the downregulation of the serum testosterone5 and
prostate-speciﬁc antigen (PSA) levels in metastatic CRPC.6-8
Although the use of estrogens is well-tolerated, a high risk of car-
diovascular events has been reported; therefore, the concomitant use
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2of low-dose oral acetylsalicylic acid (ASA) has been investigated to
reduce the risk of cardiovascular events, with major bleeding
observed.9,10 Because the availability of novel antiandrogens in
clinical practice is very recent and because of the signiﬁcant toxicity
of docetaxel in the treatment of patients with CRPC, a clinical need
exists for other therapeutic options for CRPC to avoid chemo-
therapy. Owing to the biologic and clinical efﬁcacy of the use of
estrogens in treating metastatic prostate cancer, we designed a phase
II study of low-dose EE with concomitant low-dose ASA in patients
with advanced CRPC.
Patients and Methods
Eligibility Criteria
The present study included patients with histologically conﬁrmed
advanced prostate adenocarcinoma that had relapsed after previous
treatment with luteinizing hormone-releasing hormone analogues
and antiandrogens. Patients started EE if the following criteria were
met: positive bone scan ﬁndings and a  25% increase in the PSA
level (PSA > 2 ng/mL) for patients without measurable disease or
new metastatic lesions revealed by a bone scan and a  25% in-
crease in a bidimensionally measurable tumor mass with or without
disease progression according to the PSA value.
All the patients had a baseline Eastern Cooperative Oncology
Group performance status of  2, and adequate hematologic
(leukocyte count > 3000/mm3; hemoglobin > 10 g/dL, platelet
count > 100,000/mm3), renal (serum creatinine < 2.0 mg/dL), and
hepatic (serum bilirubin < 2.0 mg/dL) function.
Eligible patients had no history of arterial thromboembolic events,
no active bleeding, and a low risk of bleeding. Patients with history of
severe cardiovascular disease, infection, uncontrolled diabetes, or
immobilization were excluded from receiving low-dose EE. EE and
ASA were discontinued in any patient who developed pulmonary
embolism, arterial thrombosis, or any cardiovascular or bleeding event
or whose platelet count decreased to < 50,000/mm3. The ethics
committee of Cremona Hospital approved the study, and all patients
provided written informed consent. The use of bisphosphonates was
allowed for all patients presenting with bone metastases.
Treatment Plan
Patients received an EE dose of 150 mg daily (50 mg 3 times daily)
with an ASA dose of 100 mg/daily (the standard dose used for
prophylaxis for cardiovascular events).11,12 Treatment was
continued until disease progression was documented on the basis of
the serum PSA level, testosterone concentration, radiographic im-
aging ﬁndings, and clinical ﬁndings. Safety and dosage compliance
were evaluated on day 15 of cycle 1 and day 1 of each subsequent
cycle, at treatment discontinuation, if applicable, and at the end of
the study. Treatment with EE was discontinued if signiﬁcant
toxicity occurred or in the case of disease progression.
Response Assessments
The serum PSA level was measured every 3 weeks. The PSA
response rate was deﬁned as the proportion of patients with a 
50% decrease in the PSA concentration from the pretreatment
baseline PSA value. PSA progression was deﬁned as an increase from
nadir of  25% and  2 ng/mL.13 Progression-free survival (PFS)
was deﬁned as the interval from the start of EE therapy until PSA
progression, radiographic progression, and/or symptomatic pro-
gression and was calculated using Kaplan-Meier estimates (Stata/IC,
version 12). The pain reported by the patient was measured at
baseline and then every 6 weeks using a translated form of the
McGill Melzack pain questionnaire. The pain response was deﬁned
as at least a 2-point reduction of the pain intensity scale or the
complete disappearance of pain.14,15 The obtained results had to be
conﬁrmed by 2 consecutive evaluations performed  3 weeks apart,
without any increase in analgesic consumption. The laboratory tests
were performed at baseline and then every 4 weeks. The serum
testosterone levels were measured only in those patients who
experienced a PSA increase with stable disease.
The radiologic investigations included abdominal and pelvic
computed tomography or magnetic resonance imaging, bone scan,
and chest radiographs. All measurable diseases were re-evaluated at
8-week intervals. In all cases, a baseline electrocardiogram and
echocardiogram were obtained, and further active cardiologic
follow-up was performed, if indicated. Bone disease progression was
deﬁned as the appearance of any new bone lesion or the progression
of existing bone metastases. A dental examination, including
orthopantomography, was performed in all patients at baseline, with
active dental surveillance performed every 3 months.
Treatment-Related Adverse Events
Toxicity was deﬁned using the National Cancer Institute Com-
mon Toxicity Criteria, version 3.0. Treatment was delayed at the
ﬁrst occurrence of any grade 2 toxicity and administered at the same
dose after returning to grade 1 or better. In the case of grade 3 or 4
toxicity, treatment was interrupted, and a maximum of 3 weeks was
allowed for recovery. In the case of a second episode of grade 3 or 4
toxicity in the same patient, treatment was resumed after recovery,
but the subsequent dose of EE was reduced.
Statistical Analysis
The primary endpoint was the PSA response. At the conception
of the present study, no robust data were available regarding the use
of EE in patients with CRPC. Assuming a response rate of
approximately 10% with regard to other hormonal therapies for
advanced CRPC and a target level of interest of 30%, with an a of
0.05 and a b of 0.80, a sample size of 25 patients was planned in
accordance with Simon’s minimax design. An incremental accrual of
20% of patients was planned owing to the possible loss of patients
during the follow-up period. The secondary endpoints were the
median PFS and the pain response. PFS was determined using the
Kaplan-Meier method to provide the median value and 95% con-
ﬁdence intervals, and the log-rank test was performed to compare
the patients stratiﬁed by the PSA response.
Results
From April 2014 to February 2015, 32 patients were enrolled to
receive low-dose EE with low-dose ASA and were evaluable for
efﬁcacy analysis. Of the 32 patients, 4 were already receiving
treatment with ASA because of other concomitant comorbidities.
The characteristics of the 32 patients are listed in Table 1. The
median age was 62 years (range, 58-76 years). The median basal
PSA level was 11.5 ng/dL, and the median PSA level at nadir was
5.6 ng/dL. The median duration of androgen deprivation therapy
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3before starting EE was 7 years. Of the 32 patients, 31 (96.8%) had
bone metastases.
During EE-based treatment, a decrease in the PSA level of �
50% was observed in 19 patients (59.3%; 95% CI, 41%-76%;
Table 2). The response was conﬁrmed at week 4 after the second
PSA level evaluation. A decrease in the PSA level of � 30% and �
90% was reported in 23 (71.8%) and 6 (18.7%) patients, respec-
tively. The waterfall plot for the PSA response is shown in Figure 1.
At the analysis (May 1, 2016), with a median treatment follow-
up period of 10 months, the median PFS was 9.4 months (95%
CI, 6.5-14.1 months). Of the 32 patients, 7 (21.8%) had not
developed disease progression. The median PFS was 14.4 months
(95% CI, 10.7 months to not reached) for patients who experi-
enced a PSA decrease of � 50% and 5.5 months (95% CI, 2.8-7.7
months) for patients without a PSA decrease of � 50% (P <
.0001; Figure 2). However, no statistically signiﬁcant difference
was observed in patients treated with > 1 line of therapy (P ¼
.60). The proportion of patients without PSA progression at 12
months was 40.6% (13 patients); 1 patient had no disease pro-
gression 24 months after the start of the combined therapies The
median PSA level in the group of patients who experienced disease
progression was 13.1 ng/dL. The main determination of progres-
sion was the biochemical PSA increase. In the 24 patients who
reported pain at baseline, pain reduction was documented in 10
(41.6%; 95% CI, 16%-50%), and the median duration of the
palliative response was 8 months.
The regimen was generally well-tolerated, and no grade 3/4
toxicity was observed. No death related to adverse events was
observed. One patient interrupted the combination of EE and ASA
because of a cardiac event. No other thromboembolic, cardiovas-
cular, or major bleeding complication events occurred during the
use of EE and ASA. One patient reported grade 2 nausea and
vomiting. Only 1 event of minor hematuria was reported, which
completely and spontaneously resolved without the need for drug
suspension. Two patients reported grade 1 asthenia. No other
relevant toxicities were reported in our patients.
Discussion
The results of our study suggest that low-dose EE with
concomitant low-dose ASA as a thromboprophylactic agent is
feasible and can achieve results in terms of the PSA response and
PFS in patients with advanced CRPC. The EE and ASA combi-
nation was associated with a PSA response rate in 59.3% of our
patients and a median PSF of 9.5 months.
Recently, 2 novel antiandrogenic therapies, abiraterone and
enzalutamide, were approved for the treatment of CRPC in the
prechemotherapy setting. Abiraterone acetate is a potent and irre-
versible inhibitor of cytochrome P17 that blocks androgen synthe-
sis, and enzalutamide is a nonsteroidal second-generation
antiandrogen that blocks different steps in the androgen receptor
signaling pathway. The efﬁcacy of the combination of EE and ASA
is modest compared with whose related to abiraterone and enzalu-
tamide shown in larger and randomized trials.4 In particular, in
Table 1 Patient Characteristics
Characteristic Value
Enrolled patients (n) 32
Age (years)
Median 62
Range 58-76
Laboratory test results
PSA (ng/mL)
Median 11.5
Range 2.5-259
Hemoglobin (g/dL)
Median 11
Range 9.1-13.6
ALP (U/L)
Median 161
Range 48-1115
LDH (U/L)
Median 248
Range 82-1213
ECOG performance status (n)
0 18
1 10
2 4
Gleason grade (n)
<8 19
�8 13
Duration of androgen deprivation therapy (years) 7
Metastatic sites (n)
Bone 31
Lymph node 20
Visceral 3
Lines of therapy
1 23
>1 9
Pain present 24
Pain requiring opiates 10
Abbreviations: ALP ¼ alkaline phosphatase; ECOG ¼ Eastern Cooperative Oncology Group;
LDH ¼ lactate dehydrogenase; PSA ¼ prostatic-speciﬁc antigen.
Table 2 Summary of Outcomes
Variable n (%)
Enrolled patients 32
PSA decline
�30% 23 (71.8)
�50% 19 (59.3)
�90% 6 (18.7)
Efﬁcacy
Median PFS (mo; 95% CI) 9.4 (6.5-14.1)
Patients without PSA progression at 12 mo 13 (40.6)
Patients with PSA progression at 24 mo 1 (3.2)
Palliative response (95% CI) 10 (41.6)
Median duration of palliative response (mo; 95% CI) 8 (5.5-9.4)
Abbreviations: CI ¼ conﬁdence interval; PFS ¼ progression-free survival; PSA ¼ prostatic-
speciﬁc antigen.
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4CRPC, abiraterone and enzalutamide resulted in a PSA response
rate in 68% and 78% of patients, respectively, compared with 43%
of patients receiving the combination of EE and ASA.4 Moreover,
the PFS for those receiving abiraterone and enzalutamide was longer
than that for those receiving EE and ASA (16.5, 20, and 9.5 months
for abiraterone, enzalutamide, and EE plus ASA, respectively).
However, the availability in clinical practice of abiraterone and
enzalutamide is recent. Previously, most patients with CRPC un-
derwent chemotherapy only. However, considering the high in-
cidences of adverse events related to chemotherapy, other agents
were investigated for the treatment of CRPC. In the scenario of
hormonal therapy, a biologic rationale exists for the use of estrogen
therapy for CRPC. Estrogens inhibit the hypothalamic-pituitary-
testicular axis through a negative feedback loop and, subsequently,
testosterone production. Therefore, estrogen therapy exerts addi-
tional hormonal effects, decreasing continued stimulation of the
androgen receptor necessary to fuel disease progression.16 In addi-
tion, estrogens might decrease adrenal androgen production by
inhibiting dehydroepiandrosterone and dehydroepiandrosterone
sulfate synthesis.16,17 Furthermore, secondary hyperexpression of
estrogen receptors in prostate cancer has been observed after pre-
vious androgen deprivation therapy.18,19 Several studies have also
shown a direct cytotoxic effect of estrogen on prostate cancer cells
in vivo and in vitro.20,21 Therefore, it is possible to speculate on a
plausible clinical use for estrogens that might guarantee a new
method of achieving castration in patients with prostate cancer
resistant to LHRH agonist activity, with a direct cytotoxic effect.
In the clinical setting, several studies on the use of oral EE were
performed that included men with advanced CRPC showing a PSA
response of approximately 70% and a median PFS ranging from 10
to 15 months for those patients exhibiting a response.6-8 Izumi
et al6 reported the positive outcomes of 24 Japanese patients with
CRPC treated with orally EE at a dose of 1.5 mg/day, and Azuma
et al7 evaluated the safety proﬁle and the efﬁcacy of a combination
therapy of etoposide and EE. Sciarra et al8 reported the data from a
large series of 112 patients with CRPC in whom � 2 lines of
androgen deprivation therapy had failed. A conﬁrmed PSA response
was found in 70.5% of the 112 patients. The median time to PSA
progression was 15.10 months. In this context, the novelty of our
study was the very low dose of EE (150 mg daily; 50 mg 3 times
daily), suggesting the activity of EE on the PSA level of patients with
CRPC is quite similar with lower dosages.
Other therapies for CRPC were investigated, such as diethyl-
stilbestrol or fulvestrant.22-25 However, although fulvestrant was
well tolerated, it failed to produce a clinical or PSA response.25
However, the combination of dexamethasone, aspirin, and the
immediate addition of diethylstilbestrol resulted in neither a greater
PSA response rate nor longer PFS compared with dexamethasone
with deferred diethylstilbestrol.23
An increased risk of thromboembolic events during EE-based
treatment has been reported.8,26,27 In the study by Sciarra et al,8
the toxicity (mainly thromboembolism) was the cause of treat-
ment cessation for > 20% of patients. To avoid and prevent this
possible complication, we enrolled only patients with a low risk of
thromboembolic events, and concomitant low-dose ASA was
administered with EE, because a recent meta-analysis reported an
ASA dose of 100 mg is safe and adequate for primary cardiovascular
disease prevention.28 In our study, the concomitant assumption of
ASA with EE might explain the possible absence of thromboembolic
events in the treated cohort. Moreover, all other adverse events
related to EE were reported in smaller percentages of patients,
suggesting that low-dose EE is adequate in term of safety.29
Patients with advanced CRPC usually have bone metastases and a
high risk of developing thrombocytopenia, which might increase the
risk of bleeding associated with ASA used as thromboprophylaxis.
Although almost all our patients had bone metastases, no major
bleeding event was reported, suggesting that low-dose ASA is a safe
prophylactic measure.
However, our study had several limitations. First, our study
included a small number of patients, precluding possible deﬁnitive
conclusions. Second, the absence of survival as an endpoint, using
instead only the PSA response, and the absence of data on androgen
levels and their changes during EE treatment were also shortcom-
ings. Finally, PFS is a mixed endpoint that included PSA progres-
sion, clinical progression, and disease progression.
Conclusion
Our results suggest that low-dose EE combined with low-dose
ASA as thromboprophylaxis is a safe regimen with activity in
Figure 2 Progression-Free Survival Stratiﬁed by the Prostate-
Speciﬁc Antigen Response (Psa)
Figure 1 Waterfall Plot for Prostate-Speciﬁc Antigen Response
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5advanced CRPC. Because low-dose EE is both less expensive and
more readily available, its clinical use should be investigated as an
addition to novel hormonal therapies for prostate cancer to improve
the cure rates and prolong the period to the start of ﬁrst-line
chemotherapy.
Clinical Practice Points
 Low-dose EE with concomitant low-dose ASA as thrombopro-
phylaxis is feasible and achieve results in terms of the PSA
response rate and PFS in patients with advanced CRPC.
 The concomitant use of ASA with EE was possibly the reason for
the absence of thromboembolic events in our study.
 The clinical use of low-dose EE should be investigated as an
addition to novel hormonal therapies for prostate cancer.
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